Skip to main content
. 2011 Oct 15;34(11):2448–2453. doi: 10.2337/dc11-0616

Table 2.

Analysis of GTT parameters by HIV status

Measure Age-restricted subjects*
P value
HIV infected (n = 309) Control (n = 187) All (n = 496)
Diabetes (2 h >200 mg/dL), % (n) 1.3 (4/309) 0 (0/187) 0.65
 OR for HIV+ vs. control subjects (95% CI) NA
IGT (2 h >140 mg/dL), % (n) 16.8 (52/309) 12.3 (23/187)
 OR for HIV+ vs. control subjects (95% CI)
  Unadjusted 1.44 (0.85–2.45) 0.17
  Adjusted for demographics 1.32 (0.76–2.30) 0.33
  Final model with AT** 0.84 (0.44–1.62) 0.61
IGT (2 h >140 mg/dL) in those without IFG100, % (n) 13.1 (33/252) 8.2 (12/146)
 OR for HIV+ vs. control subjects (95% CI)
  Unadjusted 1.68 (0.84–3.37) 0.14
  Adjusted for demographics 1.61 (0.78–3.33) 0.20
  Final model with AT** 1.14 (0.50–2.59) 0.76
2-h glucose (mg/dL)
 Median (IQR) 105.0 (83–128) 96.3 (78.3–121.3)
 Mean ± SD 108.9 ± 35.9 101.3 ± 32.7
 Mean difference HIV+ vs. control subjects (95% CI)
  Unadjusted 7.6 (1.7–13.6) 0.012
  Adjusted for demographics 7.3 (1.0–13.5) 0.023
  Final model with AT** 4.3 (−2.3 to 10.8) 0.20

P values in boldface denote statistical significance at P < 0.05. Those with fasting glucose ≥126 mg/dL or taking diabetes medication are excluded. IQR, interquartile range; OR, odds ratio.

*All analyses are age restricted to 38–52 years.

**Final model adjusts for demographics and AT.

‡IFG100 is defined as fasting glucose >100 mg/dL.